Skip to main content
Research and analysis

ESPAUR report 2025 to 2026: Chapter 1. Introduction

Published 12 November 2026

The 2025 to 2026 ESPAUR report offers the latest comprehensive analysis of the national data on antimicrobial resistance (AMR), prescribing and stewardship, and highlights the pertinent developments and trends. 

The number of patient episodes of bacteria isolated from blood (bacteraemia) increased by 22.9% between 2019 and 2025. The burden of AMR in the population, calculated by determining the incidence rates of resistance to antibiotics in organisms selected for their public health importance, increased by 16.8% between 2019 and 2025. Enterobacterales remained the predominant contributors to the AMR burden, accounting for approximately 85.5% of resistant bacteraemia episodes.  

As in previous years, in 2025 the AMR burden in bacteraemia varied markedly across different populations, ages, ethnic groups and areas. Individuals over 74 years of age accounted for almost half of all episodes and experienced the highest rates of resistance, followed by infants <1 year old. By ethnicity, individuals of ‘Asian/Asian British’ ethnicity had the highest percentage of resistant bacteraemia episodes, at 42.4%,  compared to 20.7% resistant bacteraemia episodes of individuals with ‘White’ ethnicity. The London region reported the highest AMR burden rate (44.7 per 100,000) compared to the South West (30.2 per 100,000), although AMR burden rate varied more markedly between Integrated Care Boards (ICBs) than between regions, highlighting local variation that may be masked by regional averages. Lastly, individuals living in the most deprived quintile area had AMR burden rates of 44.4 per 100,000 compared with 30.8 per 100,000 in the least deprived quintile, with this gap widening between the highest and lowest deprivation quintile from 29% in 2019 to 44.2% in 2025.

Between 2019 and 2025, the proportion of resistant bacteraemia increased across most antibiotic classes in both Escherichia coli and Klebsiella pneumoniae. However the largest resistance increase observed was to piperacillin-tazobactam in K. pneumoniae, from 15.1% in 2019 to 22.8% in 2025, almost twice the level of resistance observed in E. coli (11.9%). Rising resistance to second-line antibiotics remains a concern in both methicillin-resistant Staphylococcus aureus (MRSA)  and methicillin-susceptible S. aureus (MSSA), with resistance to macrolides and clindamycin reaching approximately 20% in MSSA and over 40% in MRSA.

In 2025, the overall rate for 30-day all-cause mortality in patients with a carbapenemase-producing organism (CPO) isolated from a sterile site specimen was 21.2% compared to 14.9% observed in blood specimens from selected Gram-negative bacteraemia (E. coli, K. pneumoniae, Pseudomonas spp., Acinetobacter spp.). Patients infected with a species resistant to one or more antibiotics had a higher overall crude mortality rate (16%) compared to those with a susceptible strain (14.4%). 

In 2025, marked geographical variation in CPO notification rates and mechanisms of carbapenem resistance was observed across England, with the North West and London reporting the highest number of CPOs, a trend observed since national reporting began. However, this variation was substantially greater at ICB-level than at regional level, indicating that regional averages may mask local areas of high burden. An example of this London, with the NHS North West London ICB reporting 36.6 CPO episodes per 100,000 population compared with NHS South West London ICB (7.5). This highlights the need for surveillance, infection prevention and control, diagnostic and antimicrobial guidelines resources that reflect local epidemiology. 

Rates of fungaemia continued to rise in 2025 reaching 4.1 fungal bloodstream infections per 100,000 population, an overall increase of 32.4% since 2019 (3.1 per 100,000). Candida albicans remained the most frequently isolated yeast species, comprising almost 40% of all fungal bloodstream infections. Candidozyma auris remained an important cause of healthcare-associated infection in England, with hospital outbreaks continuing to drive its epidemiology, and was classified as a notifiable organism in England in April 2025. In 2025, 213 patients were newly identified with C. auris, of whom 38 had invasive infection and 60% were linked to declared outbreaks, predominantly in London and the South-East of England. 

Overall total antibiotic consumption in 2025 decreased by 10.7% in 2025 compared to 2019 pre-pandemic level (2019: 17.8 versus 2025: 15.9 Daily Defined Doses (DDD) per 1,000 inhabitants per day (DID). Previous trends reflected unusual infection epidemiology trends during or post-pandemic, although in 2025 these trends stabilised reflecting a return to more historical patterns of circulating infections.  

In 2025, antibiotic consumption continued to be highest in general practice (65.3%), though this decreased from 71.8% (12.8 items per 1,000 DID) in 2019. This reduction is likely to be, in part, related to changes in data capture and access to healthcare following the introduction of the Pharmacy First service in January 2024. In 2025, antibiotic consumption was highest in the North East region (18.2 DID), where usage has consistently been the highest, while South East (14.1 DID) reported the lowest total consumption, however all regions reported lower total antibiotic use in 2025 compared with pre-pandemic 2019 and 2024 levels. These overall declines were largely driven by reductions in primary care[footnote 1] prescribing, which decreased across all regions in 2025 compared with 2024. In contrast, a third of the regions showed slight increase in consumption in secondary care, (London +5.4%, South West +1%, and Yorkshire and Humberside +0.1%).  

Overall antibiotic use in secondary care in 2025 was 4,724 DDDs per 1,000 admissions, similar to 2024 (4,709 DDDs per 1,000 admissions), remaining relatively stable since 2022. Both inpatient and outpatient antibiotic use were lower in 2025 compared with 2019 (−9% and −2%, respectively). Between 2019 and 2025, use of several antibiotics (quinolone (−21%), macrolides (−19.5%), lincosamides (−19.5%), streptogramins (−19.5%), aminoglycosides (−12.7%) and carbapenems (−2%)) in secondary care declined. The decline in carbapenem use was largely driven by reductions in meropenem prescribing (from 54.3 to 51.0 DDDs per 1,000 admissions, respectively). In contrast, prescribing of tetracyclines (+25.3%), and sulfonamides and trimethoprim (40.4%) have increased over this period. The rise in prescribing of tetracycline in 2025 (+16.2%, 715.1 to 831.1 DDDs per 1,000 admissions from 2024). This likely reflects changes in prescribing practice, including substitution away from quinolones and macrolides (both of which decreased over the same period), increased use of doxycycline in respiratory infections, and its growing role as an oral step-down option in line with the IV-to-oral switch (IVOS) antimicrobial stewardship initiative. Moreover, provision of doxycycline post-exposure prophylaxis (doxyPEP) for sexually transmitted infections (STIs) like syphilis and chlamydia, including stocking in some London trusts, may have also contributed to the increase. Increased use of sulfonamides and trimethoprim is likely to be associated with both changing epidemiology of urinary tract infections (UTIs) and antimicrobial stewardship measures, including reduced use of fluoroquinolones following the MHRA safety update issued in January 2024.

Total antifungal consumption in 2025 was 11% higher than 2019, with 87% of systemic antifungals used in the community setting. Terbinafine use has increased by 13.5% (0.836 to 0.948 DID) in primary  care between 2019 and 2025. In secondary care, where data for terbinafine use was unavailable for 2019, use increased by 68.9% between 2020 and 2025 (+68.9%, 0.006 to 0.009 DID).This increase is concerning given the emerging resistance to terbinafine in the dermatophyte Trichophyton indotineae in England highlighted in Chapter 4 (Emerging concerns – Trichophyton indotineae).

From April 2025 to March 2026, 28% of children aged 0 to 9 years received one or more antibiotics against the national target of equal to or more than 27%, with this target met in approximately half (20 out of 41, 49%) of all ICBs. Over the same period, the number of trusts that achieved any reduction in their ‘Watch’ and ‘Reserve’ antibiotic consumption against the 2019 baseline was 84 (65%). Averaged across all acute provider trusts for England, ‘Watch’ and ‘Reserve’ antibiotic consumption reduced to 4.2% below the financial year (FY) 2019 to 2020 baseline of 2,229 DDDs per 1,000 admissions. 

There was an increase of 5% in the proportion of 5-day prescriptions for amoxicillin 500mg capsules between March 2025 and March 2026, principally driven by a reduction in amoxicillin 500mg capsule seven-day courses.  

TARGET training has now reached over 3,000 primary care professionals, and the TARGET and Royal College of General Practitioners (RCGP) collaborative webinar series continues to achieve high levels of engagement and positive feedback with 2 of the 3 webinars achieving the highest satisfaction scores since the start of the collaboration. Following identification of gaps in pharmacy technicians’ knowledge, a series of workshops was developed and delivered to pharmacy technicians in collaboration with the Association of Pharmacy Technicians UK (APTUK) and NHS England. Pre- and post-webinar surveys were conducted which showed that, although knowledge levels were higher compared to a previous national study in 2019, further work is required to translate this knowledge into confidence, role ownership and routine engagement in AMS activities.   

A total of 195,796 pledges were made on the main Antibiotic Guardian (AG) pledge page from the inception of the campaign in 2014 to the end of 2025. Following findings from the 2023 UKHSA AMR public survey, UKHSA delivered phase 2 of the Andi Biotic campaign targeting messaging around correct antibiotic behaviours and AMR awareness using humour-led content to younger adults. The Andi Biotic reached 10.35 million users. In 2025, as part of UK’s actions to tackle health inequalities, the AG pledges were translated into Urdu, Punjabi, Mandarin, Polish and Romanian languages identified in the UK Census as among the most widely spoken (excluding English and Cymraeg). An evaluation of user feedback on the translated pages was conducted in collaboration with the University of Warwick and showed the translated pledges were well received, with self-reported improved AMR knowledge. For World AMR Awareness Week (WAAW) in 2025, the webpage hosting the WAAW toolkit was visited 4,849 times between publication in September 2025 and May 2026.  

A wide range of new and ongoing research projects is reported in the field of healthcare associated infection (HCAI) and AMR in the last year with over 100 peer-reviewed papers published across UKHSA, covering many of the major themes of the UK National Action Plan for AMR (NAP), including stronger laboratory capacity and surveillance in AMR, human infection prevention and control, and optimal use of antimicrobials. The latest National Institute for Health and Care Research (NIHR) Health Protection Research Unit (HPRU) in HCAI and AMR, led by the University of Oxford in partnership with the UKHSA, began in April 2025 and runs to March 2030. It brings together multidisciplinary expertise across 4 research themes: optimising surveillance, establishing population impact, advancing stewardship approached and mitigating Gram-negative infections. 

Infographics visualising the main findings from this report are available on the ESPAUR report web page.   

This report shows that AMR in England continues to increase despite lower antibiotic use than before the pandemic, with increasing proportions of drug resistance, and widening variation associated with inequalities with key differences in burden shown by ethnicity and socio-economic class. Antibiotic consumption however, has remained below 2019 levels in 2025, with continued reductions in fluoroquinolone prescribing following national AMS initiatives and updated MHRA prescribing advice. These findings highlight that while AMS remains a cornerstone of the response to AMR, sustained reductions in resistant infections will require a whole-system approach coordinating public health action, infection prevention and control, surveillance, diagnostics and preventive and clinical intervention. Better understanding of trends and the factors which shape them, will assist the development and targeting of interventions to help redress these increases and highlight the need for targeted surveillance, stewardship and prevention measures aligned with the 2024-to-2029 UK AMR NAP.

  1. Primary care includes data provided by general practice, dental practices, and other community settings (community pharmacy, out of hours and urgent care services, walk-in centres, community service and community hospitals) ↩